LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 0.9838 USD -9.74% Market Closed
Market Cap: 25.9m USD
Have any thoughts about
LAVA Therapeutics NV?
Write Note

LAVA Therapeutics NV
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

LAVA Therapeutics NV
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
LAVA Therapeutics NV
NASDAQ:LVTX
Additional Paid In Capital
$194.4m
CAGR 3-Years
68%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Additional Paid In Capital
$487.1m
CAGR 3-Years
8%
CAGR 5-Years
4%
CAGR 10-Years
6%
ProQR Therapeutics NV
NASDAQ:PRQR
Additional Paid In Capital
€416.4m
CAGR 3-Years
1%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
Additional Paid In Capital
$1.2B
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
16%
argenx SE
XBRU:ARGX
Additional Paid In Capital
$5.7B
CAGR 3-Years
19%
CAGR 5-Years
47%
CAGR 10-Years
62%
Merus NV
NASDAQ:MRUS
Additional Paid In Capital
$1.6B
CAGR 3-Years
36%
CAGR 5-Years
42%
CAGR 10-Years
N/A
No Stocks Found

LAVA Therapeutics NV
Glance View

Market Cap
25.9m USD
Industry
Biotechnology

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

LVTX Intrinsic Value
2.1828 USD
Undervaluation 55%
Intrinsic Value
Price

See Also

What is LAVA Therapeutics NV's Additional Paid In Capital?
Additional Paid In Capital
194.4m USD

Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Additional Paid In Capital amounts to 194.4m USD.

What is LAVA Therapeutics NV's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 3Y
68%

Over the last year, the Additional Paid In Capital growth was 0%. The average annual Additional Paid In Capital growth rates for LAVA Therapeutics NV have been 68% over the past three years .

Back to Top